A Wisconsin pharmacist has agreed to plead guilty to purposely trying to spoil hundreds of doses of Moderna's COVID-19 vaccine.
torontosun.com
Media mostly silent on safety concerns and lack of transparency surrounding Moderna’s experimental COVID vaccine, while stakeholders get richer.
Children's Health Defense
November 18, 2020
donate
For the second time in a week, news of a “promising”
COVID-19 vaccine sent global stock markets on a joy ride and triggered an avalanche of positive news stories which, for the most part, avoided any killjoy questions about vaccine safety or transparency.
On Monday, Moderna
announced that its
mRNA-1273 COVID vaccine candidate was 94.5% effective, based on interim Phase 3 trial data.
Last week
Pfizer announced that analysis of preliminary Phase 3 trial data indicated its BNT162b2 COVID vaccine, developed in partnership with Germany’s BioNTech, was “more than 90% effective.”
Both announcements came in the form of press releases — with neither company providing the actual data behind their claims. Though efficacy rates in the ninetieth percentile were enough to make Wall Street and most media outlets swoon, at least one publication, STAT,
pointed out what the companies themselves didn’t: Both trials are ongoing, and as they continue, efficacy rates could decline, as “it’s often the case that a vaccine performs less well in the real world than it does in the setting of a clinical trial.”Buy New $35.98(as of 05:14 EST - Details)
STAT also noted that neither company can yet say how long the vaccine, which in both cases is administered in two doses, will provide protection as that “can only be determined over time as large numbers of people are vaccinated.“
Both drugmakers said they will seek
Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for their experimental vaccines as soon as they meet the criteria. The authorization, which allows vaccine makers
to skip standard mandatory safety and compliance inspection of their vaccine manufacturing facilities, is a winner-takes-all-prize awarded exclusively to the first COVID vaccine approved by the FDA.
Both announcements triggered sharp increases in the companies’ stock prices. Moderna stock shot up by nearly15% on Monday. According to STAT, “Every Tuesday Moderna’s top doctor gets about $1million richer” by selling his existing stock like clockwork through pre-scheduled trades, “earning him more than $50 million since the dawn of the pandemic.”
For the second time in a week, news of a “promising” COVID-19 vaccine sent global stock markets on a joy ride and triggered an avalanche of positive news stories which, for the most part, avoided any killjoy questions about vaccine safety or transparency. On Monday, Moderna announced that its...
www.lewrockwell.com
People in some places will kill you for your shoes...how far do you think they would go for 50 million?
Moderna boss says COVID-19 vaccine not proven to stop spread of virus
Moderna’s
coronavirus vaccine may not get life back to normal right away because it hasn’t yet been proven to prevent the deadly bug from spreading, the company’s top doctor says.
Research has shown that the biotech firm’s shot is effective at preventing people from getting sick with COVID-19, but there’s no hard evidence that it stops them from carrying the virus “transiently” and potentially infecting others who haven’t been vaccinated, according to Dr. Tal Zaks, Moderna’s chief medical officer.
“I think we need to be careful, as we get vaccinated, not to over-interpret the results,” Zaks
told Axios in a TV interview released Monday. “When we start the deployment of this vaccine, we will not have sufficient concrete data to prove that this vaccine reduces transmission.”
Moderna’s coronavirus vaccine may not get life back to normal right away because it hasn’t yet been proven to prevent the deadly bug from spreading, the company’s top doctor says.…
nypost.com
I dunno, this does not look like a good SAFE idea to me.